ToniKChoueiriMD

Genitourinary Oncology, Hematologic Oncology

Director, Lank Center for Genitourinary Oncology; Director, Kidney Cancer Center, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, Harvard Medical School (@DrChoueiri)

Join to view full profile

Dr. Choueiri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Choueiri's full profile

Already have an account?

Office
450 Brookline av, Dana 929
Boston, MA 02115
Phone+1 617-632-5456

Fax+1 617-632-2167

Summary

Dr. Toni Choueiri is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dana-Farber Cancer Institute. He received his medical degree from St Joseph's University Medical School and has been in practice 17 years. He also speaks multiple languages, including Arabic and French. He specializes in genitourinary oncology (kidney, prostate, bladder and testicular cancers). He is a Professor of Medicine at Harvard Medical School.

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007
Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
St Joseph's University Medical SchoolClass of 2000

Certifications & Licensure

NH State Medical License 2024 - 2026
MA State Medical License 2006 - 2025
RI State Medical License 2020 - 2020
OH State Medical License 2001 - 2011

Awards, Honors, & Recognition

Schonfeld Award Kidney Cancer Association, 2016
George Canellos Award for Excellence in Clinical Investigation Dana-Farber Cancer Institute, 2013
Most Compassionate Doctor American Registry

Clinical Trials

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Start of enrollment: 2008 Dec 01
Completed
Phase 2
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC Start of enrollment: 2006 Sep 01
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling Start of enrollment: 2011 Apr 01
Withdrawn
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
Tivozanib + Gemcitabine in Metastatic RCC Start of enrollment: 2013 Jun 01
Withdrawn
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) Start of enrollment: 2014 Nov 25
Active, not recruiting
Phase 1
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 2
Savolitinib vs. Sunitinib in MET-driven PRCC. Start of enrollment: 2017 Jul 25
Active, not recruiting
Phase 3
ABEMA Alone or in COMBO With MK-6482 Start of enrollment: 2020 Dec 31
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC Start of enrollment: 2021 Oct 28
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Tejas Jammihal, Renee Maria Saliby, Chris Labaki, Hanna Soulati, Juan Gallegos
Nature Cancer. 2025-01-09
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Mehul Gupta, Connor Wells, Meredith M Regan, Wanling Xie, Vishal Navani
European Urology Oncology. 2024-12-31

Journal Articles

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic
Toni Choueiri, MD, JAMA Oncology
Rethinking Clinical Trials Reform During the COVID-19 Pandemic
Chadi Nabhan, Toni K Choueiri, JAMA Oncology
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Geographic Distribution of Racial Differences in Prostate Cancer Mortality
David F Friedlander, Kerry L Kilbridge, Paul L Nguyen, Toni K Choueiri, Adam S Kibel, Quoc-Dien Trinh, JAMA Network Open
Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status
Paul L Nguyen, Adam S Kibel, Mani Menon, Sean A Fletcher, Toni K Choueiri, Annals of Surgical Oncology
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
Rheumatologic Symptoms in Oncologic Patients on PD-1 Inhibitors
Alexandra Mulloy, Toni K Choueiri, ScienceDirect
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Determinants of Prostate Specific Antigen Screening Among Black Men in the United States in the Contemporary Era
Paul L Nguyen, Akshay Sood, Firas Abdollah, Deepansh Dalela, Moritz Hansen, Toni K Choueiri, Jesse D Sammon, Mani Menon, The Journal of Urology
Join now to see all

Lectures

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell ca...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Efficacy of Savolitinib vs Sunitinib in Patients with MET-Driven Papillary Renal Cell Carcinoma
Toni Choueiri, MD, JAMA Oncology
https://www.doximity.com/articles/ba81e72a-1a08-424c-9605-ecfc7add2d39
UpToDate, Wolters Kluwer Health - 2013-02-21

Authored Content

Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Efficacy of Savolitinib vs Sunitinib in Patients with MET-Driven Papillary Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Clinical and Genomic Characterization of Low–Prostate-Specific Antigen, High-Grade Prostate CancerFebruary 2018
Comparative Effectiveness of Robot-Assisted vs. Open Radical Cystectomy☆☆☆December 2017
Join now to see all

Press Mentions

Encouraging Phase 2 Results from LITESPARK-003 Call for Ongoing Research into Innovative First-Line Combination Therapy for Advanced Kidney CancerJanuary 17th, 2025
Advancing RCC Treatment: Biomarkers, Combination Therapies, and Emerging InnovationsJanuary 8th, 2025
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney CancerOctober 24th, 2024
Join now to see all